The collaboration is intended to combine data streams from Trinity Biotech's CGM+ wearable biosensor platform with Latch Medical's advanced drug delivery technologies to evaluate the development of precision therapeutic solutions for diabetes, obesity and other metabolic conditions. The companies will explore how real-time metabolic data generated by CGM+ can be used to help guide and optimise therapeutic delivery, creating the potential for more personalised and responsive treatment approaches.

As part of the collaboration, Trinity Biotech has also agreed in principle to make a strategic equity investment in Latch Medical, which has previously attracted strategic investment from established participants in the global drug delivery industry. Trinity Biotech’s planned investment reflects its belief in the potential importance of precision intradermal delivery technologies within next-generation metabolic health solutions.